Reuters logo
BRIEF-Bluebird bio reports updated clinical data from starbeam study
2017年6月26日 / 晚上8点18分 / 3 个月前

BRIEF-Bluebird bio reports updated clinical data from starbeam study

June 26 (Reuters) - Bluebird Bio Inc-

* bluebird bio Inc says on June 26, co reported updated clinical data from starbeam study clinical study of its lenti-d product candidate - sec filing

* 15/17 patients (88%) in initial study cohort remain free of major functional disabilities (mfds) at 24 months

* bluebird bio Inc - in starbeam study, safety profile of lenti-d was consistent with myeloablative conditioning

* bluebird bio Inc - no patients treated with lenti-d had graft versus host disease (gvhd), and there was no graft rejection or clonal dominance. Source text: (bit.ly/2sK3TP9) Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below